NCT02771054View on ClinicalTrials.gov

Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 2, 2016

Primary Completion Date

July 15, 2018

Study Completion Date

July 15, 2018

Conditions
HIV
Interventions
DRUG

TAF/FTC

Change of nucleoside backbone

Trial Locations (1)

416 85

Sahlgrenska University Hospital, Gothenburg

All Listed Sponsors
lead

Göteborg University

OTHER

NCT02771054 - Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation | Biotech Hunter | Biotech Hunter